Vertex Pharmaceuticals Incorporated
VRTX-
Vertex Pharmaceuticals Inc. dropped 0.4% to $467.98 after the biotech company posted lower income in the fourth quarter ending in December.
Revenue increased to $2.91 billion from $2.52 billion, net income dropped to $913.0 million from $968.8 million, and earnings per diluted share fell to $3.50 from $3.71 a year ago.
Revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO, a prescription medicine used for cystic fibrosis treatment.
For fiscal 2025, the company estimated revenue between $11.75 billion and $12.0 billion, compared to $11.02 billion in 2024.
Feb 11, 2025 -
Vertex Pharmaceuticals edged up 0.6% to $400.0 after the company agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, or about $65 per share.
Alpine Immune soared 36% to $64.21.
Apr 11, 2024
|
|
| |
|
| Trading Volume | 43,316 |
|
|
504.99 - 343.00 |
| Market Cap Full | $ 127.1B |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | - | 1% | 2.8% | 9.1% |
| Q2 | - | - | 12.4% | 11.7% |
| Q3 | - | - | -0.1% | -1.2% |
| Q4 | - | - | -22.1% | 17% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 1 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| 6.5 | -2.9 | -0.6 | -5.7 | 15.7 | 3.5 | 4.4 | -0.1 | - | - | - | -13.8 |
| 2023 | |||||||||||
| 11.9 | -10.2 | 8.5 | 8.1 | -5 | 8.8 | 0.1 | -1.1 | -0.2 | 4.1 | -2 | 14.7 |
| 2022 | |||||||||||
| 10.7 | -5.4 | 14.1 | 5.2 | -2.7 | 4.9 | -1.7 | 1.7 | 2.8 | 7.8 | 1.4 | -8.7 |
| 2021 | |||||||||||
| -3.3 | -7 | 1.1 | 1.5 | -4.3 | -3.5 | -0 | -0.6 | -9.4 | 2 | 1.1 | 17.5 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | 2.7 | 3 | 2.5 |
| Q2 | 3.5 | 3.1 | 0.3 |
| Q3 | 4 | 3.6 | 3.3 |
| Q4 | 0 | 3.1 | 3 |
| A | 10.18 | 12.8 | 9 |